Cue Biopharma, Inc.
NASDAQ:CUEBiotechnology
+$0.38 today
- Market cap
- $102.43M
- Beta
- 2.53
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$4.06
Volume 0.21M
Average 0.74M
CUE Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Cue Biopharma, Inc.NASDAQ: CUE
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables turns negative
Q1 FY2026 accounts payables was -$622K, compared with $961K a year earlier. Trailing-twelve-month accounts payables was -$458K. Over 3 fiscal years it compounded at +138.4% a year.
Context
- Accounts payables amounted to 4.1% of revenue in FY2025, down 3.2 pp from a year earlier.
- Accounts payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts payables holds near -$622K or moves back toward the trailing-twelve-month quarterly average of -$114.5K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- 1.13M USD
- Year-over-year change
- +265.9%
- 4-year CAGR
- +21.3%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.13M | +265.9% |
| FY2024 | 2024-12-31 | (678K) | -188.1% |
| FY2023 | 2023-12-31 | 770K | +827.7% |
| FY2022 | 2022-12-31 | 83K | -84.1% |
| FY2021 | 2021-12-31 | 520.4K | — |
Accounts Payables vs competitors
How CUE compares with its peers on the latest reported figures
- CUE's LTM Mar 2026 accounts payables of $458K is the 4th largest of the 7 companies compared; the peer median is $22.74K.
- Its year-over-year change of +239.3% is the 2nd highest of 7, against a peer median of -13.4%.
- Accounts payables amounts to 1.4% of revenue for CUE, versus a peer median of 7.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $4.9M | +28.5% | +8.8% | 1472.1% | |
| LTM Mar 2026 | $1.88M | -646.1% | — | — | |
| LTM Mar 2026 | $764K | +6466.7% | -36.8% | — | |
| LTM Mar 2026 | $458K | +239.3% | +138.4% | 1.4% | |
| LTM Mar 2026 | $424K | -76.4% | — | — | |
| LTM Mar 2026 | $109.49K | -55.4% | +121.5% | 7.7% | |
| LTM Mar 2026 | $64K | +100.9% | — | 2.8% | |
| Peer median (excluding CUE) | $22.74K | -13.4% | +8.8% | 7.7% | |
Competitors are the stored peer set for CUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (44.16M) | (53.01M) | (50.73M) | (40.67M) | (26.6M) |
| Depreciation & Amortization | (1.78M) | 1.81M | 3.44M | 2.35M | 958K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 11.52M | 9.5M | 8.18M | 6.85M | 4.74M |
| Change in Working Capital | (4.39M) | 356K | (934K) | (4.93M) | (3.3M) |
| Accounts Receivables | (1.73M) | 3.09M | (1.64M) | 753K | (6.5M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 520.4K | 83K | 770K | (678K) | 1.13M |
| Other Working Capital | (3.18M) | (2.81M) | (63K) | (5M) | 2.08M |
| Other Non-Cash Items | (26.13K) | (454K) | 90K | 74K | 2.51M |
| Operating Cash Flow | (38.84M) | (41.81M) | (39.96M) | (36.33M) | (21.69M) |
| Capital Expenditures | (913.04K) | (171K) | 0 | (66K) | (177K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 40K |
| Purchases of Investments | 0 | (29.45M) | 0 | 0 | (16.5M) |
| Sales of Investments | 10M | 5M | 25M | 0 | 16.5M |
| Other Investing Activities | 21.55K | 6K | 2K | 98K | 212K |
| Investing Cash Flow | 9.11M | (24.61M) | 25M | 32K | 75K |
| Debt Repayment | 0 | 10M | (2M) | (4M) | (4.5M) |
| Common Stock Issued | 17.38M | 39.3M | 13.39M | 14.22M | 30.79M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.85M | 4.36M | 473K | 18K | 0 |
| Financing Cash Flow | 19.23M | 53.66M | 11.86M | 10.24M | 26.29M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (10.5M) | (12.76M) | (3.1M) | (26.05M) | 4.68M |
| Free Cash Flow | (39.75M) | (41.98M) | (39.96M) | (36.4M) | (21.86M) |
Cue Biopharma, Inc.
NASDAQ:CUE
Intrinsic Alpha fair value
Locked
Current Price
$14.10
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.